Adiponectin Signaling in Colorectal Cancer

  • Gowru Srivani
  • Begum Dariya
  • Ganji Purnachandra Nagaraju
  • Afroz Alam
Part of the Diagnostics and Therapeutic Advances in GI Malignancies book series (DTAGIM)


Colorectal cancer (CRC) is an obesity-correlated malignancy. Obesity leads to dysregulation of adipocytokines. The adiponectin is an adipokine, secreted by adipose tissue, plays an essential role in energy metabolism, anti-inflammatory and insulin sensitizing properties. Besides this it also possess anti-neoplastic properties including promotion of apoptosis and inhibition of differentiation and progression of tumor cells. Adiponectin in serum/plasma level always depend on physical activity, diet and inheritance. High concentration of adiponectin are observed to play a crucial role in inhibiting tumor growth, which is also evidenced from the EPIC study where lower adiponectin circulation are at higher risk of cancer including CRC. Thus these results suggest an epidemiological link existing between obesity and cancer in association with adiponectin, playing its crucial role. Even though there are several studies reported in regard of CRC, the results with anti-cancerous property of adiponectin are still inconsistent. Adiponectin has numerous systemic effects that regulates homeostasis and constantly exists in high concentration. However, from the epidemological studies it was reported that low concentration of adiponectin are always at higher risk for CRC. The present article includes molecular evidence with a prominence on the regulation of adiponectin signalling pathways and their crosstalk with other signalling pathways in relation to CRC progression and provides several therapeutic future perspectives for the crucial role of adiponectin, aiming it as a target for the prevention of CRC.


CRC Adiponectin Obesity Inflammation Signalling pathways 





Adipocyte complement related protein 30

ADP 355

Adenosine di phosphate


Protein kinase B


Adenosine monophosphate Activated protein-kinase


Body mass index


Colorectal cancer


Disease free survival


Epidermal growth factor receptor


European prospective investigation into cancer and nutrition study


Extracellular signal—regulated kinase


Fatty acid synthase


Gelatin binding protein


Insulin—like growth factor


Insulin like growth factor binding protein-1




Mammalian target of rapamycin


Nuclear factor kappa B cells


Overall survival


Plasminogen activator inhibitor-1




Peroxisome proliferator activated receptor γ


Sirtulin (Silent mating type information regulation 2 homolog) 1


Signal transducer and activator of transcription


Tumour necrosis factor


Vascular endothelial growth factor


  1. Aleksandrova K, Boeing H, Jenab M, Bueno-de-Mesquita HB, Jansen E, van Duijnhoven FJ, Fedirko V, Rinaldi S, Romieu I, Riboli E, Romaguera D, Westphal S, Overvad K, Tjonneland A, Boutron-Ruault MC, Clavel-Chapelon F, Kaaks R, Lukanova A, Trichopoulou A, Lagiou P, Trichopoulos D, Agnoli C, Mattiello A, Saieva C, Vineis P, Tumino R, Peeters PH, Arguelles M, Bonet C, Sanchez MJ, Dorronsoro M, Huerta JM, Barricarte A, Palmqvist R, Hallmans G, Khaw KT, Wareham N, Allen NE, Crowe FL, Pischon T (2012) Total and high-molecular weight adiponectin and risk of colorectal cancer: the European prospective investigation into cancer and nutrition study. Carcinogenesis 33:1211–1218PubMedPubMedCentralCrossRefGoogle Scholar
  2. An W, Bai Y, Deng S-X, Gao J, Ben Q-W, Cai Q-C, Zhang H-G, Li Z-S (2012) Adiponectin levels in patients with colorectal cancer and adenoma: a meta-analysis. Eur J Cancer Prev 21:126–133PubMedCrossRefGoogle Scholar
  3. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J-i, Hotta K, Shimomura I, Nakamura T, Miyaoka K (1999a) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83PubMedCrossRefGoogle Scholar
  4. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J-i, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y (1999b) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83PubMedCrossRefGoogle Scholar
  5. Ashktorab H, Soleimani A, Nichols A, Sodhi K, Laiyemo AO, Nunlee-Bland G, Nouraie SM, Brim H (2018) Adiponectin, Leptin, IGF-1, and tumor necrosis factor alpha as potential serum biomarkers for non-invasive diagnosis of colorectal adenoma in African Americans. Front Endocrinol (Lausanne) 9:77–77CrossRefGoogle Scholar
  6. Barb D, Pazaitou-Panayiotou K, Mantzoros CS (2006) Adiponectin: a link between obesity and cancer. Expert Opin Investig Drugs 15:917–931PubMedCrossRefPubMedCentralGoogle Scholar
  7. Barbieri M, Esposito A, Angellotti E, Rizzo MR, Marfella R, Paolisso G (2013) Association of genetic variation in adaptor protein APPL1/APPL2 loci with non-alcoholic fatty liver disease. PLoS One 8:e71391–e71391PubMedPubMedCentralCrossRefGoogle Scholar
  8. Brusselmans K, De Schrijver E, Verhoeven G, Swinnen JV (2005) RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res 65:6719–6725PubMedCrossRefPubMedCentralGoogle Scholar
  9. Byeon JS, Jeong JY, Kim MJ, Lee SM, Nam WH, Myung SJ, Kim JG, Yang SK, Kim JH, Suh DJ (2010) Adiponectin and adiponectin receptor in relation to colorectal cancer progression. Int J Cancer 127:2758–2767PubMedCrossRefPubMedCentralGoogle Scholar
  10. Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579PubMedCrossRefPubMedCentralGoogle Scholar
  11. Canhoroz M, Kanat O, Saraydaroglu O, Buluc E, Avci N, Cubukcu E, Olmez OF, Manavoglu O (2014) Clinical significance of adiponectin expression in colon cancer patients. J Cancer Res Ther 10:347–353PubMedCrossRefPubMedCentralGoogle Scholar
  12. Chajes V, Cambot M, Moreau K, Lenoir GM, Joulin V (2006) Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res 66:5287–5294PubMedCrossRefPubMedCentralGoogle Scholar
  13. Chandrasekar B, Mummidi S, Perla RP, Bysani S, Dulin NO, Liu F, Melby PC (2003) Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. Biochem J 373:547–558PubMedPubMedCentralCrossRefGoogle Scholar
  14. Cheng KK, Iglesias MA, Lam KS, Wang Y, Sweeney G, Zhu W, Vanhoutte PM, Kraegen EW, Xu A (2009) APPL1 potentiates insulin-mediated inhibition of hepatic glucose production and alleviates diabetes via Akt activation in mice. Cell Metab 9:417–427PubMedCrossRefPubMedCentralGoogle Scholar
  15. Dai Z, Xu Y-C, Niu L (2007) Obesity and colorectal cancer risk: a meta-analysis of cohort studies. World J Gastroenterol 13:4199–4206PubMedPubMedCentralCrossRefGoogle Scholar
  16. Delort L, Jardé T, Dubois V, Vasson M-P, Caldefie-Chézet F (2012) New insights into anticarcinogenic properties of adiponectin: a potential therapeutic approach in breast cancer? Vitam Horm 90:397–417PubMedCrossRefPubMedCentralGoogle Scholar
  17. Deng Y, Scherer PE (2010) Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci 1212:E1–E19PubMedPubMedCentralCrossRefGoogle Scholar
  18. Desruisseaux MS, Nagajyothi, Trujillo ME, Tanowitz HB, Scherer PE (2007) Adipocyte, adipose tissue, and infectious disease. Infect Immun 75:1066–1078PubMedCrossRefPubMedCentralGoogle Scholar
  19. Divella R, De Luca R, Abbate I, Naglieri E, Daniele A (2016) Obesity and cancer: the role of adipose tissue and adipo-cytokines-induced chronic inflammation. J Cancer 7:2346PubMedPubMedCentralCrossRefGoogle Scholar
  20. Dossus L, Jenab M, Slimani N, Rinaldi S, Kaaks R, Cust AE, Overvad K, Fo C-C, Mesrine S, Joulin V, Linseisen J, Rohrmann S, Boeing H, Pischon T, Trichopoulou A, Trichopoulos D, Benetou V, Palli D, Berrino F, Tumino R, Sacerdote C, Mattiello A, Quirós JR, Mendez MA, Sánchez M-J, Larrañaga N, Tormo MJ, Ardanaz E, Bueno-de-Mesquita HB, van Gils CH, Peeters PHM, Khaw K-T, Bingham S, Allen N, Key T, Riboli E, Friedenreich C, Bonnet F, Laville M, Lukanova A, Lundin E, Olsen A, Tjønneland A (2007) Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. J Clin Endocrinol Metabol 92:255–263CrossRefGoogle Scholar
  21. Endo H, Hosono K, Fujisawa T, Takahashi H, Sugiyama M, Yoneda K, Nozaki Y, Fujita K, Yoneda M, Inamori M, Wada K, Nakagama H, Nakajima A (2009) Involvement of JNK pathway in the promotion of the early stage of colorectal carcinogenesis under high-fat dietary condition. Gut 58:1637–1643PubMedCrossRefPubMedCentralGoogle Scholar
  22. Fang JY, Richardson BC (2005) The MAPK signalling pathways and colorectal cancer. Lancet Oncol 6:322–327PubMedCrossRefPubMedCentralGoogle Scholar
  23. Fenton JI, Birmingham JM (2010) Adipokine regulation of colon cancer: adiponectin attenuates interleukin-6-induced colon carcinoma cell proliferation via STAT-3. Mol Carcinog 49:700–709PubMedPubMedCentralGoogle Scholar
  24. Fenton JI, Birmingham JM, Hursting SD, Hord NG (2008) Adiponectin blocks multiple signaling cascades associated with leptin-induced cell proliferation in Apc min/+ colon epithelial cells. Int J Cancer 122:2437–2445PubMedCrossRefGoogle Scholar
  25. Ferrante AW Jr (2007) Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. J Intern Med 262:408–414PubMedCrossRefGoogle Scholar
  26. Fowler JA, Lwin ST, Drake MT, Edwards JR, Kyle RA, Mundy GR, Edwards CM (2011) Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood 118:5872–5882PubMedPubMedCentralCrossRefGoogle Scholar
  27. Gavrila A, Chan JL, Yiannakouris N, Kontogianni M, Miller LC, Orlova C, Mantzoros CS (2003) Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metabol 88:4823–4831CrossRefGoogle Scholar
  28. Haggar FA, Boushey RP (2009) Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 22:191–197PubMedPubMedCentralCrossRefGoogle Scholar
  29. He J, Wang Z, Zhang S (2019) Correlation analysis of IL-4, IL-10 and APN levels with postoperative infection of colorectal cancer. Oncol Lett 17:1603–1608PubMedGoogle Scholar
  30. Hebbard LW, Garlatti M, Young LJ, Cardiff RD, Oshima RG, Ranscht B (2008) T-cadherin supports angiogenesis and adiponectin association with the vasculature in a mouse mammary tumor model. Cancer Res 68:1407–1416PubMedPubMedCentralCrossRefGoogle Scholar
  31. Higgins LS, Depaoli AM (2010) Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. Am J Clin Nutr 91:267s–272sPubMedCrossRefPubMedCentralGoogle Scholar
  32. Hiyoshi M, Tsuno NH, Otani K, Kawai K, Nishikawa T, Shuno Y, Sasaki K, Hongo K, Kaneko M, Sunami E, Takahashi K, Nagawa H, Kitayama J (2012) Adiponectin receptor 2 is negatively associated with lymph node metastasis of colorectal cancer. Oncol Lett 3:756–760PubMedPubMedCentralGoogle Scholar
  33. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao T-S, Lodish HF (2004) T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci 101:10308–10313PubMedCrossRefPubMedCentralGoogle Scholar
  34. Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata M, Yamaguchi M, Namiki S, Nakayama R, Tabata M, Ogata H, Kubota N, Takamoto I, Hayashi YK, Yamauchi N, Waki H, Fukayama M, Nishino I, Tokuyama K, Ueki K, Oike Y, Ishii S, Hirose K, Shimizu T, Touhara K, Kadowaki T (2010) Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature 464:1313–1319PubMedCrossRefPubMedCentralGoogle Scholar
  35. Jasinski-Bergner S, Kielstein H (2019) Adipokines regulate the expression of tumor-relevant microRNAS. Obes Facts 12:211–225PubMedPubMedCentralCrossRefGoogle Scholar
  36. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedPubMedCentralCrossRefGoogle Scholar
  37. Kadowaki T, Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26:439–451PubMedCrossRefPubMedCentralGoogle Scholar
  38. Kang HW, Kim D, Kim HJ, Kim CH, Kim YS, Park MJ, Kim JS, Cho SH, Sung MW, Jung HC, Lee HS, Song IS (2010) Visceral obesity and insulin resistance as risk factors for colorectal adenoma: a cross-sectional, case-control study. Am J Gastroenterol 105:178–187PubMedCrossRefPubMedCentralGoogle Scholar
  39. Kawashima K, Maeda K, Saigo C, Kito Y, Yoshida K, Takeuchi T (2017) Adiponectin and intelectin-1: important adipokine players in obesity-related colorectal carcinogenesis. Int J Mol Sci 18:866PubMedCentralCrossRefGoogle Scholar
  40. Kelesidis I, Kelesidis T, Mantzoros CS (2006) Adiponectin and cancer: a systematic review. Br J Cancer 94:1221–1225PubMedPubMedCentralCrossRefGoogle Scholar
  41. Kim AY, Lee YS, Kim KH, Lee JH, Lee HK, Jang SH, Kim SE, Lee GY, Lee JW, Jung SA, Chung HY, Jeong S, Kim JB (2010) Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol Endocrinol 24:1441–1452PubMedPubMedCentralCrossRefGoogle Scholar
  42. Körner A, Kiess W, Kaprara A, Pazaitou-Panayiotou K, Neuwirth A, Williams CJ, Kelesidis I, Bullen J, Mitsiades N, Kelesidis T, Mantzoros CS, Tseleni S (2007) Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metabol 92:1041–1048CrossRefGoogle Scholar
  43. Kim K-y, Kim JK, Han SH, Lim J-S, Kim KI, Cho DH, Lee M-S, Lee J-H, Yoon D-Y, Yoon SR (2006) Adiponectin is a negative regulator of NK cell cytotoxicity. J Immunol 176:5958–5964PubMedCrossRefPubMedCentralGoogle Scholar
  44. Landskroner-Eiger S, Qian B, Muise ES, Nawrocki AR, Berger JP, Fine EJ, Koba W, Deng Y, Pollard JW, Scherer PE (2009) Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo. Clin Cancer Res 15:3265–3276PubMedPubMedCentralCrossRefGoogle Scholar
  45. Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT (2006) Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes 55:249–259PubMedCrossRefPubMedCentralGoogle Scholar
  46. Larsson SC, Wolk A (2007) Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr 86:556–565PubMedCrossRefPubMedCentralGoogle Scholar
  47. Li H, Stampfer MJ, Mucci L, Rifai N, Qiu W, Kurth T, Ma J (2010) A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem 56:34–43PubMedCrossRefPubMedCentralGoogle Scholar
  48. Luo Z, Zang M, Guo W (2010) AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol 6:457–470PubMedPubMedCentralCrossRefGoogle Scholar
  49. Ma Y, Yang Y, Wang F, Zhang P, Shi C, Zou Y, Qin H (2013) Obesity and risk of colorectal cancer: a systematic review of prospective studies. PLoS One 8:e53916–e53916PubMedPubMedCentralCrossRefGoogle Scholar
  50. MacDougald OA, Burant CF (2007) The rapidly expanding family of adipokines. Cell Metab 6:159–161PubMedCrossRefPubMedCentralGoogle Scholar
  51. Malih S, Najafi R (2015) AdipoRon: a possible drug for colorectal cancer prevention? Tumour Biol 36:6673–6675PubMedCrossRefPubMedCentralGoogle Scholar
  52. Mao X, Kikani CK, Riojas RA, Langlais P, Wang L, Ramos FJ, Fang Q, Christ-Roberts CY, Hong JY, Kim RY, Liu F, Dong LQ (2006) APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol 8:516–523PubMedCrossRefPubMedCentralGoogle Scholar
  53. Mao L, Lin W, Nie T, Hui X, Gao X, Li K, Ding M, Tang X, Li P, Wang Y, Xu A, Liu P, Wu D (2014) Absence of Appl2 sensitizes endotoxin shock through activation of PI3K/Akt pathway. Cell Biosci 4:60PubMedPubMedCentralCrossRefGoogle Scholar
  54. Miaczynska M, Christoforidis S, Giner A, Shevchenko A, Uttenweiler-Joseph S, Habermann B, Wilm M, Parton RG, Zerial M (2004) APPL proteins link Rab5 to nuclear signal transduction via an endosomal compartment. Cell 116:445–456PubMedCrossRefPubMedCentralGoogle Scholar
  55. Miyazaki T, Bub JD, Uzuki M, Iwamoto Y (2005) Adiponectin activates c-Jun NH2-terminal kinase and inhibits signal transducer and activator of transcription 3. Biochem Biophys Res Commun 333:79–87PubMedCrossRefPubMedCentralGoogle Scholar
  56. Moon HS, Mantzoros CS (2013) Adiponectin and metformin additively attenuate IL1beta-induced malignant potential of colon cancer. Endocr Relat Cancer 20:849–859PubMedCrossRefPubMedCentralGoogle Scholar
  57. Moon HS, Liu X, Nagel JM, Chamberland JP, Diakopoulos KN, Brinkoetter MT, Hatziapostolou M, Wu Y, Robson SC, Iliopoulos D, Mantzoros CS (2013) Salutary effects of adiponectin on colon cancer: in vivo and in vitro studies in mice. Gut 62:561–570PubMedCrossRefPubMedCentralGoogle Scholar
  58. Mutoh M, Teraoka N, Takasu S, Takahashi M, Onuma K, Yamamoto M, Kubota N, Iseki T, Kadowaki T, Sugimura T, Wakabayashi K (2011) Loss of adiponectin promotes intestinal carcinogenesis in min and wild-type mice. Gastroenterology 140:2000–2008PubMedCrossRefPubMedCentralGoogle Scholar
  59. Nagaraju GP, Zhu S, Wen J, Farris AB, Adsay VN, Diaz R, Snyder JP, Mamoru S, El-Rayes BF (2013) Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer. Cancer Lett 341:195–203PubMedCrossRefPubMedCentralGoogle Scholar
  60. Nagaraju GP, Aliya S, Alese OB (2015) Role of adiponectin in obesity related gastrointestinal carcinogenesis. Cytokine Growth Factor Rev 26:83–93PubMedCrossRefGoogle Scholar
  61. Nam SY, Kim BC, Han KS, Ryu KH, Park BJ, Kim HB, Nam BH (2010) Abdominal visceral adipose tissue predicts risk of colorectal adenoma in both sexes. Clin Gastroenterol Hepatol 8:443–450PubMedCrossRefGoogle Scholar
  62. O’Connell J, Bennett MW, O’Sullivan GC, Roche D, Kelly J, Collins JK, Shanahan F (1998) Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J Pathol 186:240–246PubMedCrossRefGoogle Scholar
  63. Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Matsuda K, Yamaguchi M, Tanabe H, Kimura-Someya T, Shirouzu M, Ogata H, Tokuyama K, Ueki K, Nagano T, Tanaka A, Yokoyama S, Kadowaki T (2013) A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 503:493–499PubMedCrossRefGoogle Scholar
  64. Oren M, Damalas A, Gottlieb T, Michael D, Taplick J, Leal JF, Maya R, Moas M, Seger R, Taya Y, Ben-Ze’Ev A (2002) Regulation of p53: intricate loops and delicate balances. Ann N Y Acad Sci 973:374–383PubMedCrossRefPubMedCentralGoogle Scholar
  65. Otake S, Takeda H, Fujishima S, Fukui T, Orii T, Sato T, Sasaki Y, Nishise S, Kawata S (2010) Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. World J Gastroenterol: WJG 16:1252PubMedCrossRefPubMedCentralGoogle Scholar
  66. Otani K, Kitayama J, Yasuda K, Nio Y, Iwabu M, Okudaira S, Aoki J, Yamauchi T, Kadowaki T, Nagawa H (2010) Adiponectin suppresses tumorigenesis in Apc(min)(/+) mice. Cancer Lett 288:177–182PubMedCrossRefPubMedCentralGoogle Scholar
  67. Otani K, Ishihara S, Yamaguchi H, Murono K, Yasuda K, Nishikawa T, Tanaka T, Kiyomatsu T, Hata K, Kawai K (2017) Adiponectin and colorectal cancer. Surg Today 47:151–158PubMedCrossRefPubMedCentralGoogle Scholar
  68. Otvos L Jr, Haspinger E, La Russa F, Maspero F, Graziano P, Kovalszky I, Lovas S, Nama K, Hoffmann R, Knappe D, Cassone M, Wade J, Surmacz E (2011) Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. BMC Biotechnol 11:90PubMedPubMedCentralCrossRefGoogle Scholar
  69. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee M, Scherer PE (2003) Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin implications for metabolic regulation and bioactivity. J Biol Chem 278:9073–9085PubMedCrossRefPubMedCentralGoogle Scholar
  70. Pischon T, Lahmann PH, Boeing H, Friedenreich C, Norat T, Tjonneland A, Halkjaer J, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Guernec G, Bergmann MM, Linseisen J, Becker N, Trichopoulou A, Trichopoulos D, Sieri S, Palli D, Tumino R, Vineis P, Panico S, Peeters PH, Bueno-de-Mesquita HB, Boshuizen HC, Van Guelpen B, Palmqvist R, Berglund G, Gonzalez CA, Dorronsoro M, Barricarte A, Navarro C, Martinez C, Quiros JR, Roddam A, Allen N, Bingham S, Khaw KT, Ferrari P, Kaaks R, Slimani N, Riboli E (2006) Body size and risk of colon and rectal cancer in the European prospective investigation into Cancer and nutrition (EPIC). J Natl Cancer Inst 98:920–931PubMedCrossRefGoogle Scholar
  71. Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, Farrow S, Howells L (1999) Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 18:6013–6020PubMedCrossRefGoogle Scholar
  72. Rosen E, Eguchi J, Xu Z (2009) Transcriptional targets in adipocyte biology. Expert Opin Ther Targets 13:975–986PubMedPubMedCentralCrossRefGoogle Scholar
  73. Saxena A, Chumanevich A, Fletcher E, Larsen B, Lattwein K, Kaur K, Fayad R (1822) Adiponectin deficiency: role in chronic inflammation induced colon cancer. Biochim Biophys Acta 2012:527–536Google Scholar
  74. Scarpa M, Scarpa M, Castagliuolo I, Erroi F, Kotsafti A, Basato S, Brun P, D'Inca R, Rugge M, Angriman I, Castoro C (2016) Aberrant gene methylation in non-neoplastic mucosa as a predictive marker of ulcerative colitis-associated CRC. Oncotarget 7:10322–10331PubMedPubMedCentralCrossRefGoogle Scholar
  75. Shankar E, Vykhovanets EV, Vykhovanets OV, Maclennan GT, Singh R, Bhaskaran N, Shukla S, Gupta S (2012) High-fat diet activates pro-inflammatory response in the prostate through association of Stat-3 and NF-κB. Prostate 72:233–243PubMedCrossRefGoogle Scholar
  76. Sharma D, Wang J, Fu PP, Sharma S, Nagalingam A, Mells J, Handy J, Page AJ, Cohen C, Anania FA, Saxena NK (2010) Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology 52:1713–1722PubMedPubMedCentralCrossRefGoogle Scholar
  77. Simpson F, Whitehead JP (2010) Adiponectin—it’s all about the modifications. Int J Biochem Cell Biol 42:785–788PubMedCrossRefGoogle Scholar
  78. Slomian G, Swietochowska E, Malinowska-Borowska J, Kasperczyk S, Rogalska A, Nowak P (2014) Association between chemotherapy and plasma adipokines in patients with colorectal cancer. Pharmacol Rep 66:902–907PubMedCrossRefGoogle Scholar
  79. Song M, Zhang X, Wu K, Ogino S, Fuchs CS, Giovannucci EL, Chan AT (2013) Plasma adiponectin and soluble leptin receptor and risk of colorectal cancer: a prospective study. Cancer Prev Res 6:875–885CrossRefGoogle Scholar
  80. Song M, Gong J, Giovannucci EL, Berndt SI, Brenner H, Chang-Claude J, Curtis KR, Harrison TA, Hoffmeister M, Hsu L, Jiao S, Le Marchand L, Potter JD, Schoen RE, Seminara D, Slattery ML, White E, Wu K, Ogino S, Fuchs CS, Hunter DJ, Tworoger SS, Hu FB, Rimm E, Jensen M, Peters U, Chan AT (2015) Genetic variants of adiponectin and risk of colorectal cancer. Int J Cancer 137:154–164PubMedCrossRefPubMedCentralGoogle Scholar
  81. Sugiyama M, Takahashi H, Hosono K, Endo H, Kato S, Yoneda K, Nozaki Y, Fujita K, Yoneda M, Wada K, Nakagama H, Nakajima A (2009) Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int J Oncol 34:339–344PubMedPubMedCentralGoogle Scholar
  82. Sundaram S, Johnson AR, Makowski L (2013) Obesity, metabolism and the microenvironment: links to cancer. J Carcinog 12:19–19PubMedPubMedCentralCrossRefGoogle Scholar
  83. Tae CH, Kim S-E, Jung S-A, Joo Y-H, Shim K-N, Jung H-K, Kim TH, Cho M-S, Kim KH, Kim JS (2014) Involvement of adiponectin in early stage of colorectal carcinogenesis. BMC Cancer 14:811–811PubMedPubMedCentralCrossRefGoogle Scholar
  84. Tan X, Wang GB, Tang Y, Bai J, Ye L (2017) Association of ADIPOQ and ADIPOR variants with risk of colorectal cancer: a meta-analysis. J Huazhong Univ Sci Technol Med Sci [Hua zhong ke ji da xue xue bao Yi xue Ying De wen ban = Huazhong keji daxue xuebao Yixue Yingdewen ban] 37:161–171CrossRefGoogle Scholar
  85. Tanabe H, Fujii Y, Okada-Iwabu M, Iwabu M, Nakamura Y, Hosaka T, Motoyama K, Ikeda M, Wakiyama M, Terada T, Ohsawa N, Hato M, Ogasawara S, Hino T, Murata T, Iwata S, Hirata K, Kawano Y, Yamamoto M, Kimura-Someya T, Shirouzu M, Yamauchi T, Kadowaki T, Yokoyama S (2015) Crystal structures of the human adiponectin receptors. Nature 520:312–316PubMedPubMedCentralCrossRefGoogle Scholar
  86. Tariq K, Ghias K (2016) Colorectal cancer carcinogenesis: a review of mechanisms. Cancer Biol Med 13:120–135PubMedPubMedCentralCrossRefGoogle Scholar
  87. Tilg H, Kaser A (2009) Adiponectin and JNK: metabolic/inflammatory pathways affecting gastrointestinal carcinogenesis. Gut 58:1576–1577PubMedCrossRefPubMedCentralGoogle Scholar
  88. Toyooka S, Toyooka KO, Harada K, Miyajima K, Makarla P, Sathyanarayana UG, Yin J, Sato F, Shivapurkar N, Meltzer SJ, Gazdar AF (2002) Aberrant methylation of the CDH13 (H-cadherin) promoter region in colorectal cancers and adenomas. Cancer Res 62:3382–3386PubMedPubMedCentralGoogle Scholar
  89. Tsao T-S, Tomas E, Murrey HE, Hug C, Lee DH, Ruderman NB, Heuser JE, Lodish HF (2003) Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity different oligomers activate different signal transduction pathways. J Biol Chem 278:50810–50817PubMedCrossRefPubMedCentralGoogle Scholar
  90. Vainio H, Kaaks R, Bianchini F (2002) Weight control and physical activity in cancer prevention: international evaluation of the evidence. Eur J Cancer Prev 11(Suppl 2):S94–S100PubMedGoogle Scholar
  91. Vetvik KK, Sonerud T, Lindeberg M, Luders T, Storkson RH, Jonsdottir K, Frengen E, Pietilainen KH, Bukholm I (2014) Globular adiponectin and its downstream target genes are up-regulated locally in human colorectal tumors: ex vivo and in vitro studies. Metab Clin Exp 63:672–681PubMedCrossRefGoogle Scholar
  92. Wahl S, Drong A, Lehne B, Loh M, Scott WR, Kunze S, Tsai PC, Ried JS, Zhang W, Yang Y, Tan S, Fiorito G, Franke L, Guarrera S, Kasela S, Kriebel J, Richmond RC, Adamo M, Afzal U, Ala-Korpela M, Albetti B, Ammerpohl O, Apperley JF, Beekman M, Bertazzi PA, Black SL, Blancher C, Bonder MJ, Brosch M, Carstensen-Kirberg M, de Craen AJ, de Lusignan S, Dehghan A, Elkalaawy M, Fischer K, Franco OH, Gaunt TR, Hampe J, Hashemi M, Isaacs A, Jenkinson A, Jha S, Kato N, Krogh V, Laffan M, Meisinger C, Meitinger T, Mok ZY, Motta V, Ng HK, Nikolakopoulou Z, Nteliopoulos G, Panico S, Pervjakova N, Prokisch H, Rathmann W, Roden M, Rota F, Rozario MA, Sandling JK, Schafmayer C, Schramm K, Siebert R, Slagboom PE, Soininen P, Stolk L, Strauch K, Tai ES, Tarantini L, Thorand B, Tigchelaar EF, Tumino R, Uitterlinden AG, van Duijn C, van Meurs JB, Vineis P, Wickremasinghe AR, Wijmenga C, Yang TP, Yuan W, Zhernakova A, Batterham RL, Smith GD, Deloukas P, Heijmans BT, Herder C, Hofman A, Lindgren CM, Milani L, van der Harst P, Peters A, Illig T, Relton CL, Waldenberger M, Jarvelin MR, Bollati V, Soong R, Spector TD, Scott J, McCarthy MI, Elliott P, Bell JT, Matullo G, Gieger C, Kooner JS, Grallert H, Chambers JC (2017) Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity. Nature 541:81–86CrossRefGoogle Scholar
  93. Wang X, Martindale JL, Liu Y, Holbrook NJ (1998) The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival. Biochem J 333(Pt 2):291–300PubMedPubMedCentralCrossRefGoogle Scholar
  94. Wang C, Xin X, Xiang R, Ramos FJ, Liu M, Lee HJ, Chen H, Mao X, Kikani CK, Liu F, Dong LQ (2009) Yin-Yang regulation of adiponectin signaling by APPL isoforms in muscle cells. J Biol Chem 284:31608–31615PubMedPubMedCentralCrossRefGoogle Scholar
  95. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS (2005a) Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 97:1688–1694PubMedCrossRefGoogle Scholar
  96. Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE, Giovannucci E (2005b) A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 14:850–855PubMedCrossRefPubMedCentralGoogle Scholar
  97. Wilk S, Scheibenbogen C, Bauer S, Jenke A, Rother M, Guerreiro M, Kudernatsch R, Goerner N, Poller W, Elligsen-Merkel D (2011) Adiponectin is a negative regulator of antigen-activated T cells. Eur J Immunol 41:2323–2332PubMedCrossRefPubMedCentralGoogle Scholar
  98. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H (2004) Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 323:630–635PubMedCrossRefPubMedCentralGoogle Scholar
  99. Wu WK, Wang XJ, Cheng AS, Luo MX, Ng SS, To KF, Chan FK, Cho CH, Sung JJ, Yu J (2013) Dysregulation and crosstalk of cellular signaling pathways in colon carcinogenesis. Crit Rev Oncol Hematol 86:251–277PubMedCrossRefPubMedCentralGoogle Scholar
  100. Xu XT, Xu Q, Tong JL, Zhu MM, Huang ML, Ran ZH, Xiao SD (2011) Meta-analysis: circulating adiponectin levels and risk of colorectal cancer and adenoma. J Dig Dis 12:234–244PubMedCrossRefPubMedCentralGoogle Scholar
  101. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762PubMedCrossRefPubMedCentralGoogle Scholar
  102. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, Kawamoto S, Kubota N, Kubota T, Ito Y, Kamon J, Tsuchida A, Kumagai K, Kozono H, Hada Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Awazawa M, Takamoto I, Froguel P, Hara K, Tobe K, Nagai R, Ueki K, Kadowaki T (2007) Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13:332–339PubMedCrossRefPubMedCentralGoogle Scholar
  103. Yang X, Li J, Cai W, Yang Q, Lu Z, Yu J, Yu H, Zhang N, Sun D, Qu Y, Guo H, Wen F, Ji Y (2015) Adiponectin gene polymorphisms are associated with increased risk of colorectal Cancer. Med Sci Monit 21:2595–2606PubMedPubMedCentralCrossRefGoogle Scholar
  104. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y (2000) Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96:1723–1732PubMedCrossRefPubMedCentralGoogle Scholar
  105. Zhan Y, Ginanni N, Tota MR, Wu M, Bays NW, Richon VM, Kohl NE, Bachman ES, Strack PR, Krauss S (2008) Control of cell growth and survival by enzymes of the fatty acid synthesis pathway in HCT-116 colon cancer cells. Clin Cancer Res 14:5735–5742PubMedCrossRefPubMedCentralGoogle Scholar
  106. Zhang Y, Zhao J, Li R, Lau WB, Yuan YX, Liang B, Li R, Gao EH, Koch WJ, Ma XL, Wang YJ (2015) AdipoRon, the first orally active adiponectin receptor activator, attenuates postischemic myocardial apoptosis through both AMPK-mediated and AMPK-independent signalings. Am J Phys Endocrinol Metab 309:E275–E282CrossRefGoogle Scholar
  107. Zhou L, Zhang HF, Ning W, Song X, Liu X, Liu JX (2017) Associations of adiponectin receptor 2 (AdipoR2) gene polymorphisms and AdipoR2 protein expression levels with the risk of colorectal cancer: a case-control study. Mol Med Rep 16:3983–3993PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  • Gowru Srivani
    • 1
  • Begum Dariya
    • 1
  • Ganji Purnachandra Nagaraju
    • 2
  • Afroz Alam
    • 1
  1. 1.Department of Bioscience and BiotechnologyBanasthali UniversityVanasthaliIndia
  2. 2.Department of Hematology and Medical Oncology, Winship Cancer InstituteEmory UniversityAtlantaUSA

Personalised recommendations